Decreased susceptibility of HIV-1 to antiretroviral drugs is usually associated with sequence changes in the viral genome (genotypic drug resistance). Detection of these mutations in the viral genome can be used to predict accurately the susceptibility of the virus to all currently licensed antiretroviral drugs and thus can be used to optimise the use of antiretroviral treatment on an individual patient basis. The routine test for resistance to protease and reverse-transcriptase inhibitors generates a sequence covering the resistance associate sites in the protease and the reverse-transcriptase gene.
Baseline and/or when failing therapy
Reference Range Please contact the laboratory.
Sample Required Plasma or Serum
Sample Volume 1mL
Turnaround Time 14 days
Must have quantifiable HIV-1 viral load.